Treatment with a regimen of venetoclax and 10 days of decitabine resulted in a median overall survival of 18 months in adults with newly diagnosed acute myeloid leukemia (AML), with rates of neutropenia, infection and 30-day mortality that were “comparable” to those seen with five days of decitabine with venetoclax, researchers reported.
In the DEC10-VEN study, investigators from the University of Texas MD Anderson Cancer Center, in Houston, evaluated 168 patients aged 60 years